Barrett's Esophagus, an undiagnosed disease


 

Barrett’s dysplasia detection and endoscopic treatment


 

Deep dive in Barrx™ RFA therapy, standard of care treatment for Barrett’s Esophagus patients
 

Learn from the experts how to manage difficult Barrett’s Esophagus cases – Part 1


 

Using Barrx™ RFA beyond Barrett's Esophagus

 
 
 

Learn from the experts how to manage difficult Barrett’s Esophagus cases – Part 2


 

Barrx™ RFA radiofrequency ablation system

Reduce risk of Barrett’s esophagus progression with a proven treatment

  • The Barrx™ radiofrequency ablation system enables the removal of Barrett’s mucosa, while preserving the underlying submucosal tissue.1
  • Clinical studies have demonstrated the safety and efficacy of RFA for treating dysplastic Barrett’s esophagus.2
  • RFA can eradicate Barrett’s esophagus and reduce the relative risk of disease progression to HGD/EAC by up to 94%.*3

* 94% is the calculated relative risk reduction [ (26‑1.5)/26] = 25/26 *100.
From [25.0% (1.5% for ablation vs 26.5% for control; 95% CI, 14.1%–35.9%; P < .001]

  1. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5‑year follow‑up. Gastrointest Endosc. 2008;68:867‑876.
  2. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277‑88.
  3. Phoa KN, van Vilsteren FG, Pouw RE, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low‑grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209‑17.